DALLAS and TORONTO, Oct. 31, 2023 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) ('Perimeter' or the 'Company') – a commercial-stage medical technology company – announced the initiation of an additional clinical trial site at the University of Washington / Fred Hutch Cancer Center located in Seattle, WA..

达拉斯和多伦多，2023年10月31日/PRNewswire/-Perimeter Medical Imaging AI，Inc。（TSXV：粉红色）（OTC:PYNKF）（FSE:4PC）（'Perimeter'或'公司'）-商业阶段医疗技术公司-宣布在位于华盛顿州西雅图的华盛顿大学/弗雷德哈奇癌症中心启动一个额外的临床试验场所。。

Perimeter is conducting an ongoing multi-center, randomized two-arm pivotal clinical trial evaluating the investigational Perimeter B-Series OCT combined with its proprietary ImgAssist AI software when used during breast conservation surgeries.

Periomer正在进行一项正在进行的多中心，随机双臂关键临床试验，评估研究性Periomer B系列OCT及其在保乳手术中使用的专有ImgAssist AI软件。

Meghan R. Flanagan, MD, MPD, University of Washington/Fred Hutch Cancer Center stated, 'Recognizing the unmet need in the field of breast cancer margin visualization, we are pleased to become the most recent site to participate in this clinical study. Combining AI with high-resolution imaging has the potential to become a new standard of care during breast conservation surgery, by reducing the number of repeat surgeries and, ultimately, delivering better outcomes for patients.' .

华盛顿大学/Fred Hutch癌症中心医学博士Meghan R.Flanagan表示，“认识到乳腺癌边缘可视化领域的未满足需求，我们很高兴成为参加这项临床研究的最新网站。将AI与高分辨率成像相结合，有可能通过减少重复手术的次数并最终为患者提供更好的结果，成为保乳手术期间的新护理标准 .

Adrian Mendes, Perimeter's Chief Executive Officer stated, 'We are focused on expediting the development of our next-gen AI technology and its clinical evaluation in an ongoing pivotal trial. Our hope is that the data generated from this study will support the commercialization of Perimeter B-Series, supporting our aim to transform cancer surgery by delivering technology that improves patient outcomes and reduces healthcare costs.'.

周长首席执行官阿德里安·门德斯（Adrian Mendes）表示，“我们专注于加速下一代人工智能技术的发展及其在正在进行的关键试验中的临床评估。我们希望这项研究产生的数据将支持周边B系列的商业化，支持我们通过提供改善患者预后和降低医疗成本的技术来改变癌症手术的目标。

About Perimeter Medical Imaging AI, Inc.

关于周边医学成像AI，Inc。

Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V: PINK) (OTC: PYNKF) (FSE: 4PC) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level.

位于加拿大多伦多和德克萨斯州达拉斯的Perimeter Medical Imaging AI（TSX-V：粉红色）（OTC:PYNKF）（FSE:4PC）是一家医疗技术公司，致力于以超高分辨率，实时，先进的成像工具来解决高度未满足医疗需求的领域。我们的FDA批准的Perimeter S系列OCT系统可在美国各地使用，可在细胞水平上实时显示切除组织的横截面可视化。

The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that is currently being evaluated in a pivotal clinical trial, with support from a grant of up to US$7.4 million awarded by the Cancer Prevention and Research Institute of Texas.

具有ImgAssist AI的突破性设备指定的研究周边B系列OCT代表了我们目前正在关键临床试验中进行评估的下一代人工智能技术，并获得了癌症预防和研究的高达740万美元的资助。德克萨斯州研究所。

The company's ticker symbol 'PINK' is a reference to the pink ribbons used during Breast Cancer Awareness Month..

该公司的勾选符号“粉红色”是乳腺癌意识月份使用的粉红丝带的参考。。

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

TSX Venture Exchange及其监管服务提供商（如TSX Venture Exchange的政策中所定义）均不对本版本的充分性或准确性承担责任。

Forward-Looking Statements

前瞻性声明

This news release contains statements that constitute 'forward-looking information' within the meaning of applicable Canadian securities legislation. In this news release, words such as 'may,' 'would,' 'could,' 'will,' 'likely,' 'believe,' 'expect,' 'anticipate,' 'intend,' 'plan,' 'estimate,' and similar words and the negative form thereof are used to identify forward-looking statements.

本新闻稿包含符合适用的加拿大证券立法含义的构成“前瞻性信息”的声明。在这个新闻稿中，“可能”，“将会”，“可以”，“将会”，“可能”，“相信”，“期望”，“预期”，“打算”，“计划”，“估计”等词语和类似的词语及其否定形式用于识别前瞻性陈述。

Forward-looking information may relate to management's future outlook and anticipated events or results and may include statements or information regarding the future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter.

前瞻性信息可能与管理层的未来前景和预期事件或结果有关，可能包括有关未来财务状况，业务策略和战略目标，竞争条件，研究和开发活动，预计成本和资本支出，研究和临床测试结果的声明或信息，税收和计划以及周边地区或涉及周边地区的目标。

Without limitation, information regarding the potential benefits of Perimeter S-Series OCT, Perimeter B-Series OCT, and Perimeter ImgAssist; details regarding Perimeter's ongoing clinical trials; and the anticipated completion date of Perimeter's clinical trials, are forward-looking information. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, any particular result will be achieved.

不受限制，有关周边S系列OCT，周边B系列OCT和周边ImgAssist的潜在益处的信息；有关周边正在进行的临床试验的详细信息；以及周边临床试验的预期完成日期，是前瞻性信息。前瞻性陈述不应被视为对未来表现或结果的保证，也不一定是对是否或何时达到任何特定结果的准确指示。

No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions, and other unpredictable factors, many of which are beyond Perimeter's control.

无法保证前瞻性信息预期的任何事件都会发生或发生。前瞻性信息基于当时可获得的信息和/或管理层对未来事件的真诚信念，并受到已知或未知的风险，不确定性，假设和其他不可预测的因素的影响，其中许多因素超出了周边的控制范围。

Such forward-looking statements reflect Perimeter's c.

这种前瞻性的陈述反映了周界的c。

SOURCE Perimeter Medical Imaging, Inc.

源周边医学成像公司。